Responsive image

Common name

N-methylethanamine

IUPAC name

N-methylethanamine

SMILES

N(CC)C

Common name

N-methylethanamine

IUPAC name

N-methylethanamine

SMILES

N(CC)C

INCHI

InChI=1S/C3H9N/c1-3-4-2/h4H,3H2,1-2H3

FORMULA

C3H9N

Responsive image

Common name

N-methylethanamine

IUPAC name

N-methylethanamine





Molecular weight

59.110

clogP

-0.133

clogS

-0.933

Frequency

0.0429





HBond Acceptor

0

HBond Donor

1

Total Polar
Surface Area

12.03

Number of Rings

0

Rotatable Bond

1

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00019 Spermine Responsive image Dietary Supplements; Micronutrients; Supplements; For nutritional supplementation, also for treating dietary shortage or imbalance.
FDBD00067 Ramipril Responsive image Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Lipid Modifying Agents; Cardiovascular System; Agents Acting on the Renin-Angiotensin System; ACE Inhibitors, Plain; ACE Inhibitors and Diuretics; ACE Inhibitors and Calcium Channel Blockers; For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy.
FDBD00092 Dofetilide Responsive image Anti-Arrhythmia Agents; Potassium Channel Blockers; Cardiovascular System; Antiarrhythmics, Class III; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; CYP3A4 Inhibitors; For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm.
FDBD00107 Oxyphenonium Responsive image Muscarinic Antagonists; Parasympatholytics; Mydriatics; Alimentary Tract and Metabolism; Drugs for Functional Gastrointestinal Disorders; Synthetic Anticholinergics, Quaternary Ammonium Compounds; For the treatment of visceral spasms.
FDBD00113 Gadodiamide Responsive image Contrast Media; Paramagnetic Contrast Media; Magnetic Resonance Imaging Contrast Media; For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
FDBD00144 Lymecycline Responsive image Anti-Bacterial Agents; Antiprotozoal Agents; Tetracyclines; Antibacterials for Systemic Use; Antiinfectives for Systemic Use; For the treatment of infections and to treat acne. It may also be used to treat urinary tract infections, gum disease, and other bacterial infections such as gonorrhea and chlamydia. Lymecycline is also used commonly as a prophylactic treatment for infection by .
FDBD00156 Ropinirole Responsive image Antiparkinson Agents; Dopamine Agonists; Antidyskinetics; Nervous System; Anti-Parkinson Drugs; Dopaminergic Agents; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Alpha2 Agonists; For the treatment of the signs and symptoms of idiopathic Parkinson's disease. Also used for the treatment of restless legs syndrome.
FDBD00168 Lidocaine Responsive image Anti-Arrhythmia Agents; Voltage-Gated Sodium Channel Blockers; Anesthetics, Local; Anesthetics; Respiratory System; Ophthalmologicals; Sensory Organs; Throat Preparations; Dermatologicals; Nervous System; Cardiovascular System; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; Antiarrhythmics, Class Ib; Local Anesthetics; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Vasoprotectives; Anesthetics for Topical Use; Antipruritics, Incl. Antihistamines, Anesthetics, Etc.; Amides; Analgesics and Anesthetics; Otologicals; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inhibitors; CYP2A6 Inhibitors; CYP2A6 Inhibitors (strong); CYP2A6 Inhibitors (moderate); CYP2A6 Inducers; CYP2A6 Inducers (strong); CYP2B6 Inhibitors (strong); CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; For production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks.
FDBD00176 Atomoxetine Responsive image Adrenergic Uptake Inhibitors; Antidepressive Agents; Nervous System; Psychoanaleptics; Centrally Acting Sympathomimetics; Psychostimulants, Agents Used for Adhd and Nootropics; Cytochrome P-450 CYP2C19 Inducers; CYP2D6 Inducers; CYP2D6 Inducers (strong); CYP3A4 Inhibitors; For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.
FDBD00195 Ibutilide Responsive image Anti-Arrhythmia Agents; Cardiovascular System; Antiarrhythmics, Class III; Antiarrhythmics, Class I and Iii; Cardiac Therapy; Antiarrythmics, Class I and Iii; Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
125 , 13
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
4bgk_ligand_2_5.mol2 4bgk 1 -6.10 [N+](C)(C)(C)CC 6
4bhf_ligand_1_0.mol2 4bhf 1 -6.10 [N+](C)(C)(C)CC 6
1uv6_ligand_2_0.mol2 1uv6 1 -6.07 CC[N+](C)(C)C 6
4c5w_ligand_2_1.mol2 4c5w 1 -6.03 CC[N+](C)(C)C 6
4bgm_ligand_3_6.mol2 4bgm 1 -6.00 [N+](C)(C)(CC)C 6
3feg_ligand_3_74.mol2 3feg 1 -5.96 CC[N+](C)(C)C 6
2ha0_ligand_2_0.mol2 2ha0 1 -5.89 C([N+](C)(C)C)C 6
577 , 58